Glenmark is the first company to launch in India a Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance

Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg

Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg

Glenmark Pharma reports revenue growth of 7.2% YoY and EBITDA margin of 18.4% for Q2 FY 2022-23

Glenmark Pharmaceuticals receives ANDA approval for Sodium Phenylbutyrate Tablets USP, 500 mg

Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US

Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination for Adults with Type 2 Diabetes having Comorbidities

Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US

Glenmark Pharma reports Revenue of INR 27,773 Mn and PAT of INR 2,111 Mn for Q1 FY 2022-23

Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules,1 mg/20 mcg

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize’s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

Glenmark Pharmaceuticals launches MINYM® GEL – India’s First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

Glenmark launches Sitagliptin and its Fixed Dose Combinations, at Affordable Price for Adults with Type 2 Diabetes in India

Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited

Glenmark becomes the First Pharmaceutical Company to launch Indacaterol + Mometasone Fixed-Dose Combination Drug for Asthma in India

Glenmark Pharma reports revenue growth of 5.6% YoY Q4; 12.4% for the full year FY 2021-22

Glenmark Pharmaceuticals receives sANDA approval for Abiraterone Acetate Tablets USP, 500 mg

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

Glenmark receives the ‘India Pharma Innovation of the Year’ Award from the Government of India

Glenmark becomes the first pharmaceutical company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India

Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin’s Lymphoma

Glenmark receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg

Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules® in Columbia

Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22

lenmark launches Nitric Oxide Nasal Spray (FabiSpray®) in India for the Treatment of Adult Patients with COVID-19 in partnership with SaNOtize

Glenmark Pharmaceuticals receives ANDA approval for Metronidazole Vaginal Gel, 0.75%

Glenmark Pharmaceuticals receives ANDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and Vietnam